Tests tumor cells from children with relapsed or refractory cancers against drugs
Tests tumor cells from children with hard-to-treat leukemia or lymphoma.
Key facts
- Who runs it
- Florida International University
- Where
- Miami, United StatesSee the site
- Trial code
- Registry title
- Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 65 people, planned
- Started
- 22 Feb 2023
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional
- Treatments tested
- Functional Precision Medicine
- Record updated
- 26 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young people with cancer that came back or did not respond to treatment. Their tumor or bone marrow cells will be tested against drugs and checked for gene changes.
- Age
- 21 years or younger (from 1 day old).
- Sex
- All sexes can join.
- Disease stage
- Suspected or confirmed cancer that has come back (recurrent) or did not respond to treatment (refractory). Both solid tumors and blood cancers.
- Earlier treatment
- People with newly diagnosed tumors cannot join.
- Biomarker or test result
- No specific gene change or marker is required. A blood draw or cheek swab is taken for genetic testing.
Main reasons for not taking part
- No tumor tissue available and reachable for testing
- Not enough tumor tissue for the drug testing or genetic testing
- Newly diagnosed tumors
- Tumors with a high (>90%) cure rate with safe standard therapy
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Patients aged 21 years or younger at the time of enrollment on this study of any gender, race or ethnicity; Subjects with suspected or confirmed diagnosis of recurrent or refractory cancer Subjects who are scheduled for or have recently had biopsy or tumor excised (solid tumors) or bone marrow aspirate (blood cancers) Subjects willing to have a blood draw or buccal swab done for the purposes of genetic testing Subjects or their parents or legal guardians willing to sign informed consent Subjects aged 7 to 17 willing to sign assent
Who cannot take part
- Subjects who do not have malignant tissue available and accessible The amount of excised malignant tissue is not sufficient for the ex vivo drug testing and/or genetic profiling; Patients with newly diagnosed tumors and tumors that have high (>90%) cure rate with safe standard therapy
Where in United States
- Nicklaus Children's HospitalMiami, United StatesContact: Darika SartmatovaTaking people
About the trial
What the trial wants to find out
Functional precision medicine (FPM) is a relatively new approach to cancer therapy based on direct exposure of patient- isolated tumor cells to clinically approved drugs and integrates ex vivo drug sensitivity testing (DST) and genomic profiling to determine the optimal individualized therapy for cancer patients. In this study, we will enroll relapsed or refractory pediatric cancer patients with tissue available for DST and genomic profiling from the South Florida area, which is 69% Hispanic and 18% Black. Tumor cells collected from tissue taken during routine biopsy or surgery will be tested.
The group in the trial
- Functional Precision Medicine for Chemorefractory or relapsed patientsTreatment being tested
We intend to enroll chemorefractory or relapsed pediatric patients with all types of cancers where tumor tissue would be available for functional precision medicine that integrates ex vivo drug screening and genomic profiling. The results of the drug sensitivity assay and genetic screening will be used to inform treating physician about patient-specific drug sensitivity or resistance guiding best therapy choices.
Treatment: Functional Precision Medicine
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Advancing Personalized Treatment in Pediatric Oncology Through Functional Precision Medicine
- Plain-language title
- Tests tumor cells from children with relapsed or refractory cancers against drugsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 26 August 2026